Mark Wise, PhD

Scientist
IHMA

Disclosure(s): No financial relationships to disclose

Mark G. Wise, Ph.D.
Lead Scientist
IHMA
Schaumburg, IL 60173
USA

Mark received his Ph.D. from the University of Georgia with a focus on molecular microbial ecology. He comes to IHMA with a strong background in the diagnostics industry, previously holding various scientific positions at the in vitro diagnostics manufacturer, bioMérieux. Mark has authored several peer-reviewed publications on diverse topics, including microbial population genetics and bacterial strain typing.

Poster(s):

• 1672 - Antimicrobial Activity of Cefepime-Taniborbactam and Comparators Against Clinical Isolates from ICU and Non-ICU Patients; 2018-2020 Global Surveillance
  Saturday, October 22, 2022

  12:15 PM – 1:30 PM US ET

• 1707 - In vitro Activities of Ceftazidime-Avibactam and Comparator Agents against Enterobacterales and Pseudomonas aeruginosa Collected < 48 Hours and ≥48 Hours Post-Admission from Hospitalized Adult Patients, ATLAS Global Surveillance Program 2017-2020
  Saturday, October 22, 2022

  12:15 PM – 1:30 PM US ET

• 1708 - In vitro Activities of Ceftazidime-Avibactam and Comparator Agents against Enterobacterales and Pseudomonas aeruginosa Collected < 48 Hours and ≥48 Hours Post-Admission from Hospitalized Pediatric Patients, ATLAS Global Surveillance Program 2017-2020
  Saturday, October 22, 2022

  12:15 PM – 1:30 PM US ET

• 1709 - In Vitro Activity of Ceftazidime-Avibactam and Comparator Agents Against MDR Enterobacterales and Pseudomonas aeruginosa Collected in Latin America, ATLAS Global Surveillance Program 2018-2020
  Saturday, October 22, 2022

  12:15 PM – 1:30 PM US ET

• 1710 - In Vitro Activity of Cefepime-Taniborbactam and Comparators Against a Global Collection of Carbapenem-Resistant Enterobacterales and Carbapenem-Resistant Pseudomonas aeruginosa With and Without Carbapenemases
  Saturday, October 22, 2022

  12:15 PM – 1:30 PM US ET